Resumo

RUIZ RAMOS, J. et al. Analysis of the causes leading to withdrawal of the treatment with triple antiviral therapy for hepatitis C patients. Farm Hosp. [online]. 2014, vol.38, n.3, pp.223-226. ISSN 2171-8695.  https://dx.doi.org/10.7399/FH.2014.38.3.1171.

Objective: To assess causes of suspension of hepatitis C treatment in patients receiving triple antiviral therapy (peginterferon + ribavirin + protease inhibitor). Methods: Retrospective observational study of patients who recived triple antiretroviral therapy agaisnst hepatitis C between January 2012 - March 2013 and discontinued their treatment. Results: Of 156 patients who initiated therapy, 41 discontinued treatment: Nineteen due to adverse events, being dermatological events in seven patients ( 36.8 %), intolerance in six (31.6%) and hematologic toxicity in four (15.8%) . Sixteen patients discontinued treatment for beeing ineffectiveness. Patients with higher inefficacy failure rate were "null-responders" (32.3% ) while the group of "relapsers" were the one with the highest rate of toxicity suspensions (15.6%). Two patients died during treatment for pneumonia. Conclusions: Triple therapy with boceprevir and telaprevir is associated with a significant number of treatment failures due to toxicity and ineffectiveness.

Palavras-chave : Telaprevir; Boceprevir; Effectiveness; Safety.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )